These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20136913)

  • 1. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis.
    Broshtilova V; Gantcheva M
    Dermatol Ther; 2010; 23(1):90-3. PubMed ID: 20136913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
    Angelova-Fischer I; Tsankov N
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):115-9. PubMed ID: 16200338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis.
    Yanase DJ; David-Bajar K
    J Am Acad Dermatol; 2001 Jan; 44(1):89-93. PubMed ID: 11148482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Montelukast in general pediatric practices.
    Ngamphaiboon J
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S348-51. PubMed ID: 16623053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults.
    Capella GL; Grigerio E; Altomare G
    Eur J Dermatol; 2001; 11(3):209-13. PubMed ID: 11358726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial.
    Veien NK; Busch-Sørensen M; Stausbøl-Grøn B
    J Am Acad Dermatol; 2005 Jul; 53(1):147-9. PubMed ID: 15965438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema.
    Friedmann PS; Palmer R; Tan E; Ogboli M; Barclay G; Hotchkiss K; Berth-Jones J
    Clin Exp Allergy; 2007 Oct; 37(10):1536-40. PubMed ID: 17850382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Leukotriene antagonist. All around talent in asthma and allergies].
    MMW Fortschr Med; 2002 Nov; 144(47):64. PubMed ID: 12532531
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukotriene receptor antagonists--a novel therapeutic approach in atopic dermatitis?
    Kägi MK
    Dermatology; 2001; 203(4):280-3. PubMed ID: 11752812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cysteinyl leukotriene receptor antagonist on CD11b and CD23 expression in asthmatic children.
    Gagro A; Aberle N; Rabatić S; Ajduk J; Jelacić J; Dekaris D
    Clin Exp Allergy; 2004 Jun; 34(6):939-44. PubMed ID: 15196283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis.
    Hon KL; Leung TF; Ma KC; Wong Y; Fok TF
    J Dermatolog Treat; 2005 Feb; 16(1):15-8. PubMed ID: 15897161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Leukotriene receptor antagonists--possible therapeutic option in the treatment of atopic dermatitis ].
    Czarnecka-Operacz M; Jenerowicz D
    Pol Merkur Lekarski; 2003 Jan; 14(79):86-8. PubMed ID: 12712839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA).
    Lee SY; Kim HB; Kim JH; Kim BS; Kang MJ; Jang SO; Seo HJ; Hong SJ
    Clin Exp Allergy; 2007 Oct; 37(10):1487-93. PubMed ID: 17883728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study.
    Lehtimäki L; Petäys T; Haahtela T
    Int Arch Allergy Immunol; 2009; 149(2):150-3. PubMed ID: 19127072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast in allergic diseases beyond asthma.
    Leonardi S; Marchese G; Marseglia GL; La Rosa M
    Allergy Asthma Proc; 2007; 28(3):287-91. PubMed ID: 17619556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montelukast can reduce the severity and extent of atopic dermatitis.
    Holme H; Winckworth LC
    J Paediatr Child Health; 2013 May; 49(5):412-5. PubMed ID: 23647765
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists.
    Rackal JM; Vender RB
    Skin Therapy Lett; 2004 Feb; 9(2):1-5. PubMed ID: 14749843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.
    Meltzer EO; Malmstrom K; Lu S; Prenner BM; Wei LX; Weinstein SF; Wolfe JD; Reiss TF
    J Allergy Clin Immunol; 2000 May; 105(5):917-22. PubMed ID: 10808172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients].
    Concha del Río LE; Arroyave CM
    Rev Alerg Mex; 2003; 50(5):187-91. PubMed ID: 14631590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all.
    Chin WK
    J Clin Pharm Ther; 2018 Feb; 43(1):159-162. PubMed ID: 29114905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.